GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
|
Synonyms: SMT-026738
Compound class:
Synthetic organic
Comment: SMT-738 is from a novel class of antibacterial compounds that have activity against carbapenem-resistant Enterobacteriaceae (CREs) [1]. The structure is claimed in patent WO2022233886A1 that was filed by Discuva Ltd. (acquired by Summit Therapeutics in 2017) [2]. Functionally, it inhibits LolCDE [1], a complex that is essential for the transport of lipoproteins from the inner membrane to the outer membrane of Gram-negative bacteria.
|
|
|||||||||||||||||||||||||||||||||||
| Bioactivity Comments |
| SMT-738 exhibits a narrow-spectrum of antibacterial activity, that is selective for Enterobacteriaceae and with limited activity against human gut commensals [1].The MIC90 for antibacterial activity against multi-drug resistant (MDR) clinical isolates of Escherichia coli and Klebsiella pneumoniae is in the range of 1-2 μg/ml in vitro [1]. |